Next, we evaluated whether the immune cell alterations detected in patients with a history of GDM and with insulin treatment during pregnancy were related to metabolic measures for insulin sensitivity and body metabolism both within the first year postpartum (Visit 1) and at Visit 2 by using exploratory data analysis. This evidence concerns the gene INS and gestational diabetes.